Single nucleotide polymorphism analysis in application to fine gene mapping by Pungliya, Manish S
Worcester Polytechnic Institute
Digital WPI
Masters Theses (All Theses, All Years) Electronic Theses and Dissertations
2001-05-02
Single nucleotide polymorphism analysis in
application to fine gene mapping
Manish S. Pungliya
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/etd-theses
This thesis is brought to you for free and open access by Digital WPI. It has been accepted for inclusion in Masters Theses (All Theses, All Years) by an
authorized administrator of Digital WPI. For more information, please contact wpi-etd@wpi.edu.
Repository Citation
Pungliya, Manish S., "Single nucleotide polymorphism analysis in application to fine gene mapping" (2001). Masters Theses (All Theses, All
Years). 642.
https://digitalcommons.wpi.edu/etd-theses/642
SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS IN 
APPLICATION TO FINE GENE MAPPING 
by 
Manish Sampat Pungliya 
 
A Thesis submitted to the Faculty of the 
 
WORCESTER POLYTECHNIC INSTITUTE 
 
in partial fulfillment of the requirements for the 
 
Degree of Master of Science 
 
In 
 
Biology 
 
By 
 
___________________ 
May 2001 
 
APPROVED BY: 
 
 
Dr. Julia Krushkal , Major Advisor  Dr. Elizabeth Ryder, Advisor on Record 
 
 
Dr. Carolina Ruiz, Thesis Committee Dr. David Adams, Thesis Committee   
 
 
 
Dr. Ronald Cheetham, Head of the Department 
 ii 
ABSTRACT 
Single nucleotide polymorphisms (SNPs) are single base variations among 
groups of individuals. In order to study their properties in fine gene mapping, I 
considered their occurrence as transitions and transversions. The aim of the study was 
to classify each polymorphism depending upon whether it was a transition or 
transversion and to calculate the proportions of transitions and transversions in the 
SNP data from the public databases. This ratio was found to be 2.35 for data from the 
Whitehead Institute for Genome Research database, 2.003 from the Genome 
Database, and 2.086 from the SNP Consortium database. These results indicate that 
the ratio of the numbers of transitions to transversions was very different than the 
expected ratio of 0.5. To study the effect of different transition to transversion ratios 
in fine gene mapping, a simulation study was performed to generate nucleotide 
sequence data. The study investigated the effect of different transition to transversion 
ratios on linkage disequilibrium parameter (LD), which is frequently used in 
association analysis to identify functional mutations. My results showed no 
considerable effect of different transition to transversion ratios on LD. I also studied 
the distribution of allele frequencies of biallelic SNPs from the Genome Database. 
My results showed that the most common SNPs are normally distributed with mean 
allele frequency of 0.7520 and standard deviation of 0.1272. These results can be 
useful in future studies for simulating SNP behavior. I also studied the simulated data 
provided by the Genetic Analysis Workshop 12 to identify functional SNPs in 
candidate genes by using the genotype-specific linkage disequilibrium method. 
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INTRODUCTION 
 At the present time, we are at a stage where we can read nearly the entire 
genetic code of the human genome, as recently a rough draft of the human genome 
sequence has been determined (International Human Genome Sequencing 
Consortium 2001; Venter et. al 2001). It represents the sequence of A, G, C, and T 
letters that are symbols for nucleotides. The specific sequence of these nucleotides 
constitutes all our genes that have specific characteristics and expression in the 
human being. These genes are responsible for various physical, physiological and 
pharmacological activities in the body. Since mutations in these genes are often the 
cause of many heritable diseases, it is sometimes necessary to find specific genetic 
mutations responsible for a particular disease. This is one of the current aims of the 
Human Genome Project. 
 Until now, genome analysts have concentrated their efforts on finding the 
similarities between different individuals, and they have found that 99.9 percent of 
anyone’s genes perfectly match those of another individual (Brown 2000). But the 
remaining 0.1 percent of the genes varies among individuals. It is these nucleotide 
variations that are of interest to many researchers, as these variations might change 
the properties of tha t particular gene. Even a simple single nucleotide polymorphism 
(SNP) in a gene sequence can change the property of that gene and cause a disease, as 
differences in DNA of that gene could change the phenotype. Below I describe the 
properties of SNPs in more detail. 
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Single Nucleotide Polymorphism 
 SNPs are the most common single base variations in the human population. A 
SNP is a variation where two alternative bases occur at appreciable frequency (the 
frequency of each base is above 1% in a population) (Lander et. al 1998). Most of 
these variants are neutral, but some are functional. One of the important goals of 
genetic analysis is to identify those SNPs and SNP variants (alleles), which are 
associated with a disease. For example, consider the following nucleotide sequence, 
AATTTCCGG 
 
AATTACCGG 
The change from T to A is considered a SNP provided both alleles are present in 
more than 1 percent in the population. SNPs are often binary, i.e. they most often 
have only two alleles. They are less susceptible to mutations than microsatellite 
repeat markers. A microsatellite is a short sequence of repeated nucleotides in a 
genome e.g.: AATGAATGAATG-----, where AATG is repeated a variable number of 
times. Due to their stability, SNPs are very useful for studying human evolutionary 
history.  
 
Importance of SNPs  
The occurrence of SNPs is approximately one in every 1000-2000 base pairs, and 
the total number of SNPs in the human genome estimated by November 2000 is 
1,433,393 (The International SNP Map Working Group 2001) and 2,104,820 (Venter 
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et. al 2001). These polymorphisms are present in coding as well non-coding regions. 
Less than 1% of all the SNPs are present in the protein-coding regions of the genome 
(Venter et. al 2001). This suggests that a very small proportion of SNPs may be 
responsible for phenotypic variation.  
 
SNPs in association analysis 
 Association analysis and linkage analysis are methods for gene mapping of 
complex human disorders. In the case of association analysis, one tries to find an 
association between a marker locus (could be a SNP) and a disease locus (may be or 
may not be a SNP) from the genetic data of the human population (Risch and 
Merikangas 1996). Such analysis tests for association of loci at short distances apart 
and attempts to identify individual mutations. SNPs are therefore very useful in 
association analysis, as SNPs are so frequent and close to each other that the loci stay 
associated even after much recombination. In contrast, in linkage analysis, one tests 
for genetic linkage between a disease locus and a marker locus which is generally a 
microsatellite marker (Kruglyak et al. 1996). The distances detected in linkage 
analysis are generally much larger than those in association analysis.  In linkage 
studies, one needs to have a family with a certain proportion of individuals with the 
disease. Linkage analysis takes into account all the available information from a 
pedigree of a chromosomal region and a trait that cosegregate. Such sample data are 
often difficult to obtain. This disadvantage is overcome by using association analysis, 
as it does not require the pedigree information for a trait.  
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 Association analysis does not involve the creation of a model based on the 
pedigree information. In fact, it is based on the association that exists between two 
phenotypes or loci when they occur together in a group of individuals more often than 
expected by chance. Association may or may not be due to linkage, as in linkage one 
tries to find an association between two loci in a pedigree.  
 Association analysis is a very useful tool in mapping genes for complex 
phenotypes. An etiology of a complex phenotype can be associated with factors such 
as marker locus, disease gene, other disease genes, environment, and cultural factors. 
All of these factors interact with each other in a very complex way, resulting in the 
expression of that phenotype. The main purpose of an association study to map 
disease genes and find causative mutations is to minimize the effect of other genetic, 
environmental, and cultural factors, and in turn increase the correlations of marker 
and disease gene with the complex phenotype. By increasing the number of marker 
loci, one can improve the efficacy of association studies in finding functional 
mutations, as there is always an increased probability of finding at least one marker 
locus associated with the disease gene.  
The disadvantage of a linkage study compared to an association study lies in its 
basic requirement of number of affected individuals necessary to detect the linkage to 
a complex trait (Risch and Merikangas 1996). This number is very large when the 
proportion of affected individuals in a population is small. In contrast, the 
requirement of such number is vastly less in association methods as one tries to study 
association between a single locus or multiple loci together with the disease locus in 
affected/unaffected individuals. One would have better understanding of the 
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association of a disease locus with other loci that lie on the same chromosome or on 
different chromosomes when genome-wide association tests are performed. 
 
Linkage disequilibrium 
To investigate the association between the two loci/multiple loci, one of the 
ways of evaluating association is to use a parameter called linkage disequilibrium. 
Linkage disequilibrium mapping is a frequently used analytical approach involving 
SNPs. Linkage disequilibrium (LD) is defined as a nonrandom association between 
SNPs in proximity to each other (Terwilliger and Weiss 1998). So if thousands of 
SNPs are mapped over the entire genome, then through LD, associations could be 
established between any of the susceptibility regions of the gene and a particular SNP 
marker. Two sites are said to be in linkage disequilibrium if the presence of one 
marker locus at one site enhances the predictability of another locus on the same 
chromosome or different chromosome. This indicates that these two sites are 
associated, and it helps in mapping the disease gene, as one of the loci could be the 
disease locus, or might be associated with the disease locus so that it is transmitted in 
a family.   
 
 
 
 
 
 
 
            (A,a)                             (B,b) 
 
         locus 1        locus 2 
 
 
 
 
 
 
 
 
 
                AB  Ab  aB  ab  
 
Figure 1: Linkage disequilibrium phenomena (see text for explanation) 
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Suppose there are two loci, 1 and 2, that are close to each other (Figure 1). Loci 1 
and 2 may be on the same or on different chromosomes with two alleles each: A,a 
and B,b respective ly. As a result, there are four haplotypes possible: AB, Ab, aB, and 
ab. If allele A has a frequency of rA in the population and allele B has a frequency of 
rB, then haplotype AB would have frequency rArB in the absence of association, as 
they would occur independent of each other in the population. If alleles A and B are 
associated, then the frequency of haplotype AB would be rArB + D, where D is the 
measure of the strength of LD between the two loci 1 and 2.  
D = rAB - rArB 
If allele B at locus 2 is a disease causing locus, then the frequency of allele A would 
be much higher in affected individuals than in unaffected individuals because of its 
association with B. This method of association analysis is used in case-control 
studies. In case-control studies, there are two samples, one of cases (with disease) and 
one of control (no disease) individuals. The two groups are further classified 
according to one marker on the basis of its presence or absence. By performing chi-
square analysis, one can estimate the significance of the association of the marker 
with the disease. This method can be extrapolated to markers having more than one 
allele (reviewed by Elston 1998). 
Thus if one has a large map of such marker loci over the entire genome, one can 
test them to find the linkage disequilibrium with the disease locus of interest. The 
markers are generally polymorphisms like microsatellites, or single nucleotide 
polymorphisms within or outside the gene, but lying close to it so that they could be 
associated with the disease locus. This is the basis for linkage disequilibrium mapping 
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of common disease genes. Linkage disequilibrium mapping is considered as the 
indirect strategy (Kruglyak 1999) of association studies, as it involves testing for 
associations between the disease locus and nearby polymorphism which is not 
physically linked to the disease gene. It is done by using a dense map of polymorphic 
markers across the genome which can be tested for association with the disease locus. 
Biallelic single nucleotide polymorphisms are the markers of choice for this kind of 
analysis because of their abundance in the genome and low mutation rates compared 
to microsatellites. This is particularly important for whole-genome association studies 
for identification of complex disease genes (Schafer and Hawkins, 1998). Lai et al 
(1998) have proved the feasibility and importance of creating such SNP maps for 
identification of genes of interest. The importance of creating a dense map of SNPs is 
that it is useful in linkage disequilibrium mapping so that a susceptibility allele and a 
marker lie within the range of linkage disequilibrium (McCarthy and Hilfiker 2000). 
In the second half of this thesis, I have presented the application of association 
analysis to a simulated data set.  
Recent ly, it has been shown that the average extent of linkage disequilibrium in 
the general human population is approximately 3kb; thus roughly 500,000 SNPs (as 
markers) may be needed for systematic whole-genome linkage disequilibrium studies 
(Kruglyak 1999) so that one would have good placing of SNP markers (in the range 
of 3kb) over the entire genome. LD tends to decrease when the distance between the 
markers is in the range of 10-100kb, as there is a high probability of recombination 
and genetic drift with increased distance (McCarthy and Hilfiker 2000). 
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Application of SNPs in Pharmacogenomics 
Linkage disequilibrium mapping has also been important in pharmacogenomic 
studies (McCarthy and Hilfiker 2000). The use of LD mapping using SNPs has 
gained a lot of importance, as it provides the necessary information about the drug 
response in a genetically heterogeneous population used in clinical trials. It will help 
to uncover the secret of why some drugs are effective in certain people and not in 
others. These small variations may cause differences in drug response among patients 
as they alter gene expression. Some drugs may have a beneficial effect on some 
patients, but might prove harmful to others. So in the future a simple genetic test may 
determine whether an individual can be treated effectively by a given drug. Such 
application of genomics to pharmaceuticals is categorized as Pharmacogenomics, 
which is the branch of genomics addressing molecular pharmacology and toxicology. 
Hopefully this new branch will help reduce the cost of drug development  (presently 
it is in the range of $400-500 million), at the same time increasing the speed of the 
development process (Rothberg, Ramesh and Burgess 2000). Pharmacogenomics 
involves detecting and cataloguing SNPs in genes responsible for drug response. This 
will uncover the variability of individual drug responses, and facilitate appropriate 
patient selection during clinical trials and the aftermarket of a particular drug.   
 
 
Other applications  
SNPs are present in any part of the human genome. If they are present in the 
coding or regulatory part of the gene, a SNP variant might alter gene function, and 
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thus may be related to the disease progression. However, if a SNP is not functional it 
is still important in mapping studies, as it might be present very close to the disease 
gene. This is an important basis of linkage disequilibrium analysis as one can study 
the presence of that particular SNP in a population to find out its association with the 
disease gene in the population.  
 
Presence of SNPs  
 The presence of SNPs is related to nucleotide substitutions in DNA sequences. 
To study the process of nucleotide substitutions, several mathematical models based 
on the probability of nucleotide substitutions have been proposed in the literature 
(reviewed by Li 1997). The two simplest and most frequently used models are 
1) Jukes and Cantor’s (1969) one-parameter model and 
2) Kimura’s (1980) two-parameter model 
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1) Jukes and Cantor’s one-parameter model  
  
        Purines A    G 
 
 
    Pyrimidines C    T     
 
 Fig.2: One -parameter model (Jukes and Cantor 1969) 
  
This model assumes the substitution of nucleotides in DNA sequences is a 
random process with all possible changes occurring with equal probabilities. For 
example, nucleotide A can change to nucleotides T or C or G with equal probability. 
Let a be the rate of substitution per time in each of the three possible directions of 
nucleotide A. In this model, the rate of substitution for each nucleotide is 3a. Because 
only one parameter (a) is involved in this model, it is called a one-parameter model.  
 The basic assumption of the one-parameter model (that all nucleotide 
substitutions occur randomly) is unrealistic in most cases. For example, transitions 
(changes between A and G, or between C and T) are generally more frequent than 
transversions (changes between A and C or T, and between G and C or T, and vice 
versa). To take this fact into account, a two-parameter model was proposed by 
Kimura (1980). 
a 
a 
a 
a 
a a 
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2) Kimura’s (1980) two-parameter model  
This model attempts to account for different frequencies of transitions and 
transversions (Figure 3). In this model, there are two parameters involved. One is a, 
which is the rate of transition (changes within purines or pyrimidines) and the other is 
b , which is the rate of transversion (changes between purines and pyrimidines). If 
transitions and transversions occur with equal rates (a = b), the expected ratio 
between all possible transitions and all possible transversions from the two-parameter 
model would be, 
Ntransitions/Ntransversions = a/2b  = 0.5 
as there are four possibilities of transitions and eight possibilities of transversions. 
  Figure 3: Two-parameter model (Kimura 1980) 
 
 One- and two-parameter models of nucleotide substitutions may not apply to a 
relatively short evolutionary time and also the possibility of occurring four types of 
transitions (or eight types of transversions) with the same rate may not be true. There 
  
        Purines A    G 
 
 
    Pyrimidines C    T    
a 
b 
a 
b 
b b 
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are many other substitution models, some of which were described by Li (1997). 
These models are more complicated mathematically and take into account complex 
nucleotide substitution matrix, as some of these higher models are based on six-
parameters or nine-parameters substitution matrix (as these models consider different 
rates of substitutions within transitions or transversions). Felsenstein’s (1981) 
suggested the equal- input model, which is based on the equal rate of substitution of 
one nucleotide with the other three nucleotides (similar to the one-parameter model). 
Hasegawa et al. (1985) suggested a newer model (Model HKY85) with the addition 
of additional substitution parameters and base frequencies. All these models are 
mathematically complicated to compute. Felsenstein’s, Jukes and Cantor’s and 
Kimura’s models are special cases of Hasegawa’s model. Felsenstein’s model takes 
into account the ratio of transition to transversion equal to 1.0. Jukes and Cantor’s 
model (one-parameter model) considers equal nucleotide frequencies and transition to 
transversion ratio to 1.0, while Kimura’s model (two-parameter model) considers 
only equal nucleotide frequencies.   
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THESIS OBJECTIVES 
In the first part of my work, I investigated the exact ratio of transition to 
transversion in SNPs from the publicly available databases and compared it with the 
expected ratio of 0.5 (a = b). I also studied the distribution of the most common 
SNPs from one of the data sets explained in the next section. 
In previous studies, most association methods that used SNPs did not take into 
account the possible differences between the rates of transitions and transversions. 
These studies considered the transition and transversion occurring with equal rates as 
in the one-parameter model. To investigate the validity of this approach, after finding 
the actual proportion of transitions/transversions in the public databases, I studied the 
effect of different transition to transversion ratios (including observed and expected) 
on fine gene mapping using computer simulations. 
In the second part of this thesis, I describe how association methods are 
applied for fine gene mapping using simulated SNP data from Genetic Analysis 
Workshop 12 (GAW 12). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part I 
  Investigation of the effect of the transition to 
transversion ratio 
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METHODS 
DATA COLLECTION 
 To find out the ratio of transition to transversion in the SNP data, the SNPs 
from human chromosome 6 were collected. I selected human chromosome 6 
specifically because it has a number of genes associated with human diseases such as 
breast cancer, hypertension  (Krushkal et al. 1999), maple syrup urine disease 
(Nobukuni et al. 1991), diabetes mellitus (Davies et al. 1994), psoriasis (Balendran et 
al. 1999), and schizophrenia (Cao et al. 1997)1. I used three publicly available 
databases to collect the data: 
1) Whitehead Institute of Biomedical Research/MIT Center for Genome 
Research2   
2) The Genome Database 3 
3)  The SNP Consortium Ltd 4 
 
1) Whitehead Institute of Biomedical Research/MIT Center for Genome 
Research   
This center started work on SNPs with the intention of developing a 
dense map of SNPs (about 100,000 in number) (Collins, Guyer, and 
Chakravarti 1997). This database has an anonymous list of SNPs from both 
coding and noncoding regions of the genome. The SNPs are listed on a 
                                                 
1 http://www.ncbi.nlm.nih.gov:80/htbin-post/Omim/getmap?d2417 
2 http://www-genome.wi.mit.edu 
3 http://www.gdb.org 
4 http://snp.cshl.org 
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genetic distance map (cM) with corresponding sequence tagged sites (STSs) 
(Lander et al. 1998). The output is shown in Appendix 1.  
 
2) The Genome Database (GDB)  
This database is a result of an international collaboration in support of 
the Human Genome Project. It has the list of genes for each chromosome. In 
this database, the list of SNPs, labeled as point variations, is provided for 
individual genes. Another advantage of the GDB is that it also provides the 
allele frequencies for many polymorphisms, which is useful in finding the 
allele frequency distribution for SNPs in human population. The data 
collected from this database are in Appendix 2. 
 
3) The SNP Consortium Ltd 
This is the most comprehensive SNP database. The SNP Consortium 
Ltd. is a non-profit foundation organized for the purpose of providing public 
genomic data. This database was one of the goals of Genome II, the next 
phase of the Human Genome Project (Brower 1998). Its mission was to 
develop up to 100,000 SNPs distributed evenly throughout the human genome 
and to make the information related to these SNPs available to the public 
without intellectual property restrictions. SNP screening is performed at the 
three major genomic centers (Washington University at St. Louis, The 
Whitehead Institute for Biomedical Research and The Sanger Center), by 
using a panel of unrelated, anonymous individuals. The fifth release (April 
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2000) of this database consisted of 296,990 SNPs from all the chromosomes. 
In the present thesis, I collected data from the fifth release of this database. An 
example of this data is shown in Appendix 3. 
 
ALLELE FREQUENCY DISTRIBUTION 
 SNPs are generally present in biallelic form, but sometimes they are present in 
more than two forms. I investigated the distribution of the frequencies of the most 
common alleles in the SNP data obtained from The Genome Database (GDB). I only 
considered biallelic SNPs in this data set. The Genome Database has given the allele 
frequency for biallelic polymorphisms. I considered those allele frequencies that are 
more than 0.5 (More than 0.5 indicates frequent occurrence of that allele).  
To check the symmetry and normality of the data, I performed a kurtosis plot 
analysis to test if the data are normally distributed and also to verify that the 
distribution is not skewed to the left or right of the mean. By using symmetry and 
kurtosis measures, the normality of the allele frequency data was assessed. The null 
hypothesis of population normality was tested by using the test statistic, 
   K2 = Z2g1 + Z2g2   
 where Z2g1 and Z2g2 are the parameters for symmetry and kurtosis. K2 has 
the same distribution as c2 and it is the parameter for assessing normality using 
symmetry (Zg2) and kurtosis (Zg2) measures. Zg1 is the parameter for testing the 
population’s symmetry. But not all symmetrical distributions are normal and to check 
the normality, kurtosis measure is used. Here, Zg2 is the population kurtosis 
parameter. The calculations of Zg2 and Zg2 are as follows. 
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2g  is the sample statistic for the measure of kurtosis and for further calculations 
of 2g  refer (Zar 1999 (b)). 
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SIMULATION STUDY 
 To study the effect of different ratio of transitions to transversions, I generated 
sequence data by using a computer simulation program called TREEVOLVE (Grassly 
and Rambaut, unpublished) 1. 
 
Principle of TREEVOLVE 
 TREEVOLVE simulates DNA sequences based on Kingman’s (1982a,b,c) 
coalescent approach (cited in Kingman 2000). The coalescent model simulates the 
evolutionary history of a gene backwards in time until it reaches a point of most 
recent common ancestor (MRCA) for that gene. This generates a tree for a particular 
gene in the population sample. The tracing backwards in time is based on a Markov 
chain (Kingman 2000). An example shown in the following figure (figure 4), 
 
     MRCA (most recent common ancestor)   
         Past 
 
 
 
         Present Generation 
   1         2    3                  4          5 
Figure 4: Simulation of population history by TREEVOLVE. 
 
                                                 
1 http://evolve.zoo.ox.ac.uk 
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 According to this figure, if there are n members of a particular generation, 
then TREEVOLVE traces their family tree backward through time until it coalesces 
(i.e. the lineages find a common ancestor). The number n is reduced by one each time 
coalescence occurs so that next time (n-1) lines (members) will be traced back until 
they coalesce and so on, until the number of lines is reduced to one (MRCA). While 
simulating the tree, the program does not take into account any sequence information 
from the present-day generation individuals. The lineages are joined randomly back 
in time. Depending on the number of replicates specified in the input parameter file, a 
new random tree is generated in each replication. Each tree corresponds to a separate 
replicate.  After generating each tree, the molecular sequences are simulated down the 
genealogy under the substitution model specified by a user.  
 
Substitution model 
 For each tree, TREEVOLVE generates present-day sequences. The number of 
sequences depends on the input parameter file shown in figure 6.  The sequences 
differ completely between the replicates. After generating each coalescent tree, the 
DNA sequences are generated according to the genealogy down the line with time 
(forward direction) starting at the most recent common ancestor (MRCA) as shown in 
figure 5. TREEVOLVE has an option of using different substitution models based on 
the type of analyses and the choice of variables in the sequence generation. Two of 
the models are F84 (Felsenstein and Churchill 1996) and HKY85 (Hasegawa et al. 
1985) that takes into account the transition to transversion ratio and also the base 
frequencies as parameters, but differing in their values. I used the one- and two-
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parameter models which can be presented as a partial case of F84 model with equal 
base frequencies in all simulations. In the case of the one-parameter model which 
assumes equal rate of transitions and transversions, I used the transition to 
transversion ratio (a/2b) of 0.5. When I used the two-parameter models, the ratio of 
a/2b  was varied between 1, 2.35, 3 and 5. First of all, for a given set of simulation 
parameters, TREEVOLVE generates 200 trees (200 replicates). For each tree, it 
generates present-day sequences depending on the selected substitution model. Each 
tree corresponds to a separate replicate and these sequences differ completely 
between the replicates. While simulating these sequences TREEVOLVE also takes 
into account the mutation rate and recombination rate. As a result, some polymorphic 
sites within each replicate are produced. An example of an input parameter file for 
TREEVOLVE is shown in figure 6, and the complete list of parameters for 
TREEVOLVE used in this study is shown in table 1. The simulations were carried 
out under no recombination, and also with recombination rates varied between 10-8, 
3´10-5 and 10-3 as suggested by other studies (Zollner and Haeseler 2000) keeping all 
other parameters constant. I used no population subdivision (m = 0 in figure 6), no 
migration, and no exponential growth (e = 0.0 in figure 6) to minimize the effect of 
admixture, allelic heterogeneity and environment. The mutation rate was 10-7, which 
was constant in all simulations, as suggested by other studies (Zollner and Haeseler 
2000). I used a sequence length of 1000bp with 200 sequences (same as sample size) 
for each file. The substitution model used was either a one- or two-parameter model 
as described earlier. The simulations were performed as shown in table 2. A sample 
run of TREEVOLVE is shown in figure 7.  
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MRCA (most recent common ancestor) 
 
 
 
 
 
      1              2       3                 4   5  
Figure 5: Se quence simulation by TREEVOLVE after the population  
history has been simulated.  
 
 
 
BEGIN TVBLOCK 
[sequence length] l1000 
         [sample size] s200 
[mutation rate] u0.0000001 
[number of replicates] n1 
[substitutionmodel] vF84 t0.5 [f0.25,0.25,0.25,0.25] [r0.1667,0.1667,0.1667,0.1667, 
0.1667, 0.1667] 
        [output coalescent times] oCoal.Times 
[diploid] 
        [generation time/variance in offspring number] b1.0 
 
         *PERIOD 1 
                [length of period] t100000.0 
                [population size] n100000 e0.0 
                [subdivision] d1 m0 
                [recombination] r0.0 
        *END 
 
Figure 6: An example of input parameter file for TREEVOLVE. 
 
 
Past 
Present 
Generation 
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Table 1: Input parameter values for TREEVOLVE used in this study. 
 
Sequence length, l 1000 bp 
Sample size, s 200 sequences 
Mutation rate, u 0.0000001 
Number of replicates, n 200 
Substitution model, m One- and two-parameter model 
Transition/transversion ratio, t Varies (0.5 to 5.0) 
Base frequencies, f Equal (0.25) 
Rate heterogeneity None 
Ploidy Diploid 
Generation time/var. in offspring no., b 1.0 
Run time for population dynamic model,t 100000.0 
Effective population size, n 100000 
Exponential growth rate, e 0.0 
Number of demes, d 1 
Migration rate, m 0.0 
Recombination rate Varies from 0.0 to 10-3 
 
  
 
 
 
 
Parameters Value 
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Sequence1 TCAGGAACAACAGCTAATGAGCTTATATTTTCATGACATAACG 
Sequence2 TCAGGAACAACAGCTAATGAGCTTATATTTTCATGACATAACG 
Sequence3 TCAGGAACAACAGCTAATGAGCTTATATTTTCATGACATAACG 
Sequence4 TCAGGAACAACAGCTAATGAGCTTATATTTTCATGACATAACG 
Sequence5 TCAGGAACAACAGCTAATGAGCTTATATTTTCATGACATAACG 
Sequence6 TCAGGAACAACAGCTAATGAGCTTATATTTTCATGACATAACG 
Sequence7 TCAGGAACAACAGCTAATGAGCTTATATTTTCATGACATAACG 
 
Figure 7: A sample output of TREEVOLVE for sample size of 7 with sequence 
length of 43. There are no SNPs in nucleotide sequences shown because only 
few initial bases are shown for each sequence for illustration. 
 
 
  
Table 2: The table indicating different simulations performed for different 
parameters.  
Recombination rate Transition 
Transversion 0.0 10-8 3´10-5 10-3 
0.5 Ö Ö Ö Ö 
1.0 Ö Ö Ö Ö 
2.35 Ö Ö Ö Ö 
3.0 Ö Ö Ö Ö 
5.0 Ö Ö Ö Ö 
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LINKAGE DISEQUILIBRIUM ANALYSIS OF SIMULATED 
DATA FROM TREEVOLVE  
 Different types of software are used in order to compute values of LD (linkage 
disequilibrium) using the sequence data. In the present study, program Arlequin1 
(Schneider et al. 1997) was used for calculating the LD in the data simulated by 
TREEVOLVE. It is versatile software available for analysis of genetic data of various 
different types, including RFLPs, DNA sequence, and microsatellite data. It allows 
one to perform a number of statistical tests using population data, including linkage 
disequilibrium analysis. Arlequin has a graphical interface that is user-friendly. Its 
other advantage is that one can run a number of input files simultaneously with the 
same or different parameter lists by creating a batch file, thus reducing the analysis 
time of the user. An example of an input file of Arlequin used in this study is shown 
in figure 8. 
During analysis by Arlequin, there were 200 input files (replicates from 
TREEVOLVE) for each set of parameters. All these input files were analyzed 
together by creating a batch file (figure 9). 
 
 
 
 
 
 
                                                 
1 http://anthro.unige.ch/arlequin/ 
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[Profile] 
      Title="SNPAnalysis Ratio5 r0.0" 
      NbSamples=1 
 
             GenotypicData=0 
            DataType=DNA 
            LocusSeparator=NONE 
  MissingData='?' 
 
[Data] 
 
      [[Samples]] 
 
         SampleName="Replicate1" 
         SampleSize=10 
         SampleData= { 
sequence1 1 ACAACAGCTAATGAGCTTATATTTTCATGACATAACGGGAAC  
sequence2 1 ACAACAGCTAATGAGCTTATATTTTCATGACATAACGGGAAC 
sequence3 1 ACAACAGCTAATGAGCTTATATTTTCATGACATAACGGGAAC 
sequence4 1 ACAACAGCTAATGAGCTTATATTTTCATGACATAACGGGAAC 
sequence5 1 ACAACAGCTAATGAGCTTATATTTTCATGACATAACGGGAAC 
} 
 
Figure 8: Sequence.arp – An input file for Arlequin for the calculation of LD. 
The field under SampleData is the output of treevolve with transition to 
transversion ratio of 0.5 and recombination rate of 0.0 (Only first five sequences 
are shown with only forty nucleotides in each sequence. The data simulated by 
TREEVOLVE had 200 such sequences with 1000 nucleotides in each sequence 
for each set of parameters).   
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replicate1.arp 
replicate 2.arp 
replicate 3.arp 
replicate 4.arp 
replicate 5.arp 
replicate 6.arp 
replicate 7.arp 
replicate 8.arp 
replicate 9.arp 
replicate 10.arp 
 
Figure 9: Batch.arb – An example  of a Batch file for Arlequin. During analysis, 
100 to 200 replicates were analyzed in each batch file.  
 
 
 Arlequin calculates LD by doing pair-wise comparisons between different 
SNPs within each replicate. The LD is calculated by using the formula,  
Dij = rij - ri rj, 
where rij is the frequency of the haplotype having allele i at the first locus and allele j 
at the second locus, and ri and rj are the frequencies of alleles i and j in the replicate 
respectively.   
 After obtaining the linkage disequilibrium (D) values for all the input 
parameter files, I calculated the mean D and standard deviation (SD) values for all the 
combined 200 replicates for each parameter file (i.e. for different transition to 
transversion ratios at different recombination rates). 
  
 28
RESULTS 
SUMMARY OF DATA COLLECTED 
 In order to test whether the ratio of transitions to transversions is 0.5 (a/2b) as 
predicted, I collected SNP data from three databases. The summary of the SNP data 
collected is given in table 3. The results indicate tha t the transition to transversion 
ratio in the real data is at least four times higher than the expected ratio of 0.5.   
 
Table 3: Data Summary from all the three databases 
Dataset Number of SNPs a/2b 
The Whitehead Institute of 
Genome Research 
146 2.35 
The Genome Database 36 2.003 
The SNP Consortium 5102 2.086 
 
 
1) The Whitehead Institute of Genome research 
The SNP data is shown in appendix 1. The distribution of SNPs in this data is 
shown below in figure 10. The observed ratio of a/2b  is 2.35, which is approximately 
five times higher than the expected ratio of 0.5. The total number of biallelic SNPs in 
this dataset was 146. 
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Proportion of SNPs: 
 
      Proportion 
A/G, G/A: 25+24 = 49 0.336 
A/C, C/A: 10+4 =   14 0.096 
A/T, T/A: 3+5 =   08 0.055 
G/C, C/G: 6+7 =   13 0.089 
G/T, T/G: 5+3 =   08 0.055 
C/T, T/C: 24+30 =  54 0.370 
          ------------  
             Total = 146 
 
 
Proportion of transitions and transversions: 
        Proportion 
Transitions- 
A/G + G/A + C/T + T/C = 103     0.705 
Transversions-   
A/T + T/A + A/C + C/A + G/T + T/G + G/C + C/G = 43  0.300 
 
Figure 10: SNP distribution in the chromosome 6 data from The Whitehead 
Institute of Genome Research. 
 
  
2) The Genome database  
The SNP data from this database are shown in appendix 2. The distribution of 
SNPs in this database is shown in figure 11. The observed ratio of a/2b  is 2.003, 
which is four times higher than the expected ratio of 0.5. There were 36 biallelic 
SNPs in this dataset.  
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Proportion of SNPs: 
 
      Proportion 
A/G, G/A: 06+07 = 13 0.361 
A/C, C/A: 01+01 =  02 0.055 
A/T, T/A: 01+01 =  02 0.055 
G/C, C/G: 04+01 =  05 0.139 
G/T, T/G: 02+01 =  03 0.083 
C/T, T/C: 10+01 =  11 0.305 
                       -----------  
Total =  36 
 
Proportion of transitions and transversions: 
          Proportion 
Transitions -     
A/G + G/A + C/T + T/C = 24      0.667 
Transversions -   
A/T + T/A + A/C + C/A + G/T + T/G + G/C + C/G = 12   0.333 
 
Figure 11: SNP distribution in the chromosome 6 data from The Genome 
Database. 
 
 
 
3) The SNP Consortium Database  
An example of the SNP data from the fourth release of the SNP Consortium 
Database is shown in appendix 3. The distribution of SNPs in this dataset is given in 
figure 12. The total number of biallelic SNPs in this data set was 5102. The observed 
ratio of a/2b  is 2.09 which is four times higher than the expected ratio of 0.5. The 
total number of biallelic SNPs in this data set is 5102. This number is much higher 
than that for the first two data sets.  
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Proportion of SNPs: 
 
     Proportion 
A/G, G/A: 1750  0.343 
A/C, C/A:  425  0.083 
A/T, T/A:  342  0.067 
G/C, C/G:  432  0.085 
G/T, T/G:  454  0.089 
C/T, T/C: 1699  0.333 
            -----------  
Total = 5102 
 
Proportion of transitions and transversions: 
          Proportion 
Transitions -     
A/G + G/A + C/T + T/C = 3449      0.676 
Transversions -   
A/T + T/A + A/C + C/A + G/T + T/G + G/C + C/G = 1653   0.324 
 
 
Figure 12: SNP distribution in the chromosome 6 data from The SNP 
Consortium. 
 
 The results showing the number of SNPs are summarized in table 3. This table 
indicates that transitions are much more common than transversions, and therefore a 
two-parameter model may better describe the SNP properties than the one-parameter 
model. The overall results from figures 10, 11, and 12 are summarized in table 4. 
Table 4: Summarized results from figures 10, 11, and 12. 
Database Transitions  Transversions  Transitions/transversions  
1 103 43 0.705/0.300 = 2.35 
2 24 12 0.667/0.333 = 2.003 
3 3449 1653 0.676/0.324 = 2.086 
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ALLELE FREQUENCY DISTRIBUTION 
The main aim was to understand the distribution of SNP variants in human 
population. This knowledge may be helpful in the future when generating simulated 
SNP data.    
 To see the distribution of the allele frequencies in the human population of the 
SNPs, I analyzed the allele frequency data collected for the SNPs from the Genome 
Database. I selected those alleles which were common (i.e. they have a frequency of 
more than 0.5). The distribution of allele frequencies is shown in figure 13. This 
distribution suggests that the allele frequency of most common alleles in SNP data 
follows a normal distribution with mean allele frequency of 0.7520 and standard 
deviation of 0.1272.  
 From the Kurtosis plot analysis performed to see the symmetry and normality 
of the allele frequency data, 
K2 = 2.016915 (0.25 < P < 0.50) (From the Chi-squared distribution)   
                                                       table with two degrees of freedom) 
 Thus, the result of K2 indicates that the data are normally distributed. These 
results will help in the future for simulations of SNP data while considering the allele 
frequencies.  
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Figure 13: Allele frequency distribution for all common alleles of SNPs from 
human chromosome 6. 
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EFFECT OF THE RATIO OF TRANSITIONS TO 
TRANSVERSIONS ON LINKAGE DISEQUILIBRIUM 
 In order to study the effect of different ratios of transition to transversion on 
linkage disequilibrium, which is a frequently used parameter in association analysis, a 
simulation study was performed. After running the simulations for each set of 
parameters and analyzing the simulated data by Arlequin, I calculated the mean 
linkage disequilibrium values for each set of parameters. The results of this analysis 
are shown in the table 5.  
 
 
Table  5: Mean linkage disequilibrium values ± standard deviation for different 
values of the transition to transversion ratios at different recombination rates. 
 
Recombination rate  Transition/transversion 
(a/2b) 0.0 10-8 3´10-5 
0.5 0.0178 ±0.0393 0.0221 ±0.0454 0.0001 ±0.0006  
1.0 0.0214 ±0.0420 0.0236 ±0.0495 0.00014 ±0.0007  
2.35 0.0211 ±0.0426 0.0175 ±0.0423  0.00011 ±0.0006  
3.0 0.0193 ±0.0394 0.0205±0.0475  0.00008 ±0.0006  
5.0 0.0183 ±0.0386 0.0158 ±0.0391  0.00012 ±0.0007  
 
 The relationships between different transition to transversion ratios and mean 
LD at three recombination rates of 0.0, 10-8 and 3´ 10-5 are shown in figures 14, 15 
and 16, respectively, with error bars indicating standard deviation (SD). No variable 
loci were observed for data simulated under the highest recombination rate (10-3). I 
also observed a variation in the number of polymorphic loci for different 
 35
recombination rates, with the number of SNP loci decreasing as the recombination 
rate increased.  
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Figure 14: Plot of Mean LD Vs. a/2b at recombination rate (r) equal to 0.0.  
Error bars indicate the standard deviations (SD) 
 
 
 
 
 
 
 
  
 
 
 
Figure 15: Plot of Mean LD Vs. a/2b at recombination rate (r) equal to 10-8. 
Error bars indicate the standard deviations (SD) 
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Figure 16: Plot of Mean LD Vs. a/2b at recombination rate (r) equal to 3´10-5 
Error bars indicate the standard deviations (SD) 
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DISCUSSION 
 According to the one-parameter model, the expected ratio of transitions to 
transversions is 0.5 (since the transition rate is expected to be equal to the rate of the 
transversion). To see the actual proportion of transitions to transversions in the 
general human population, I collected data from publicly available databases. The 
ratio observed from the SNP data from the public databases showed that transitions 
are more frequent than transversions (transitions are approximately four times higher 
than transversions). Therefore, the two-parameter model (where transition and 
transversion rates differ) may better approximate the SNP behavior. My analyses 
showed that the proportion of transitions to transversions was very different (70% to 
30%, 66% to 33%, and 68% to 32% in the Whitehead Institute of Genome Research, 
the Genome Database and the SNP Consortium databases respectively) than that 
expected (33% to 66%) under the scenario of no differences in mutation rates 
between different nucleotide changes.    
 To study the distribution of the frequencies of the most common alleles in the 
SNP data obtained from The Genome Database (GDB), I considered all biallelic 
SNPs in this data set. The allele frequency distribution of the most common alleles 
turned out to be normal with mean allele frequency of 0.7520 and standard deviation 
of 0.1272. After performing the Kurtosis plot analysis on this allele frequency data, it 
showed that the distribution of allele frequency is symmetric as well as normal (K2 = 
2.016915, corresponding to 0.25 < P < 0.50). This analysis will help in the future for 
simulating SNP behavior, because allele frequencies play an important role in 
detecting strong association between a marker SNP and a susceptibility loci. If 
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marker allele frequencies are substantially different from susceptibility allele 
frequencies, then one needs a large sample size or a large number of markers or both 
to have a strong association (McCarthy and Hilfiker 2000). Therefore, the allele 
frequency distribution of common SNPs would help for future simulation studies 
involving SNP behavior in application to association studies involving allele 
frequencies.   
 I analyzed the effect of different transition to transversion ratios (a/2b) on 
linkage disequilibrium. Results from the linkage disequilibrium analysis of simulated 
population showed that the linkage disequilibrium remained approximately same for 
different transition to transversion ratios for the parameters used in the simulations. 
The results obtained were for a sequence lengths of 1000 bp. As the recombination 
rate increased, the mean LD value decreased. The increase in recombination rate also 
resulted in reduction of number of polymorphic loci, thus reducing the strength of 
LD. The reduction in number of loci could be related to the small sequence length 
(1000 bp) in simulations and high recombination rate. An average extent of useful 
levels of LD in the general human population is approximately 3kb as shown by 
Kruglyak (1999). It is possible that the a/2b  ratio might have an effect on LD when 
longer sequence length is used. Longer sequences can be investigated in future 
studies. One can also analyze the transitions and transversions separately from the 
SNP data obtained from the simulation studies. In the present study, the LD was 
evaluated between the polymorphic loci without considering whether each SNP was a 
transition or transversion.  
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 No polymorphic sites were observed in the sequences simulated by 
TREEVOLVE for recombination rate of 10-3. This result was observed with short 
sequence length and high recombination rate, which reduces the strength of LD 
considerably, because the chances of a polymorphism being fixed in a population are 
considerably less at a higher recombination rate while simulating the sequences. This 
phenomenon is because of the way the TREEVOLVE simulates the data. The 
program tries to simulate a polymorphism in the population while generating the 
sequences and not while simulating the population tree. When the recombination rate 
is much higher than the mutation rate, TREEVOLVE simulates a population that does 
not have polymorphism. These results support those previously obtained by Kruglyak 
(1999), in an independent analysis, in which he found no LD at recombination rate of 
3´10-4 or higher (corresponding to physical distance of approximately 30kb). At such 
a high rate of recombination, there is higher separation between polymorphic loci. 
Such a high separation is probably unable to be accommodated in a sequence length 
of 1000 bp, resulting in the absence of any polymorphic loci in the population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part II 
 
Application of SNPs in fine gene mapping
 41
INTRODUCTION 
 As described in the earlier part of this thesis, association analysis has been of 
considerable importance in various fields ranging from population genetics, 
pharmacogenomics, population genetic epidemiology and toxicology. An association 
is said to exist between two phenotypes (of which one is resulting into a disease) if 
they occur in the same individual more often than expected by chance. To investigate 
whether the two phenotypes are associated or not, one collects the two groups of 
individuals, one with the affected individuals and one for controls (unaffected 
individuals). Then by counting the proportion of individuals having disease and the 
other phenotype and individuals with disease and not having the other phenotype, one 
can perform a standard 2´2 chi-square allelic association analysis or a 3´2 chi-square 
genotypic association analysis to examine the significance of the association. 
 A combination of alleles at a specific gene characterizes a genotype of an 
individual. Alleles and genotypes play a very important role in association analysis. If 
a gene is a disease pre-disposing gene, it is possible that only one of the alleles of that 
gene is actually responsible for the disease predisposition. Therefore, an allelic 
association was a common way of fine gene mapping until recently, although allelic 
heterogeneity may complicate this method (Terwilliger and Weiss 1998). Thus, 
genotypic association analysis can be used in place of allelic association. In allelic 
association, alleles are used to identify an association with disease. In contrast, in 
genotypic analysis one looks at association of a disease with genotypes (similar to 
genotypic linkage disequilibrium described by Weir 1996). In genotypic association 
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analysis one studies differences in genotype frequencies in healthy and affected 
individuals to find if any genotype is associated with the disease.  
 
Objective   
 In this part, I describe an approach for fine gene mapping using SNPs from a 
general population by using genotype-specific disequilibrium analysis. The approach 
is different from the allelic disequilibrium analysis, because it considers the frequency 
of a genotype and not of individual alleles.  
 
Description of the simulated data   
 A committee of Genetic Analysis Workshop 12 (GAW12) organized by 
Southwest Foundation for Biomedical Research, San Antonio, Texas, USA, simulated 
the data for GAW12 2000. The data used in this thesis were simulated for a large 
general population. The disease prevalence in the population was about 25%. The 
data were provided for 23 extended pedigrees with 1497 total individuals (1000 
living) in the population. The disease was more prevalent in females than in males. 
Five quantitative risk factors (Q1 to Q5) and two environmental factors (E1 and E2) 
were also associated with the disease. Seven major genes (MG1 to MG7) influence 
these five quantitative risk factors as shown in the figure 17. A major gene is a gene 
related to the disease risk. The overall summary of the generating model is shown in 
figure 17. This model was not known during the analysis. In the data available to me, 
each living individual had information on affectation status, age at last exam, age at 
onset of disease if affected, five quantitative risk factors and two environmental 
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factors as well as genotypic data for SNPs present in 7 candidate genes. These genes 
were named from 1 through 7. These seven candidate genes were the genes, which 
were potential candidates that might affect the disease. The data for these seven 
candidate genes were provided by the GAW12 for analysis. These candidate genes 
were present in the major genes. The goal of the study described in this thesis was to 
test whether any of these candidate genes were contributing to the disease, and to 
identify any functional SNPs that could be related to the disease risk. The data were 
provided for 50 such replicates (50000 living individuals). There were 165 founders 
in each replicate. There was a total of 9515 original SNPs in the population of 50,000 
individuals. The organizers also provided us with the information about which was 
the best replicate in the data. The best replicate was replicate 42 that had the data with 
contributions from all the factors discussed above. It represented the best sample 
population among all 50 replicates, with the mean simulated parameters being the 
closest to the parameters originally used I simulations.   
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Figure 17: The phenotypic model of the data simulated by GAW12. Boxes 
indicate items provided in the GAW12 data set, including quantitative traits, 
affectation status, age at onset, environmental factors (E1 and E2) and household 
membership (HH). Circles indicate genetic factors including seven major genes 
and a mitochondrial (Mito) component.  
 
 
 
 
MG5 MG1 
MG6 
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METHODS 
 
Individuals used in the study   
 The study was performed on pedigree founders as well as all the living  
pedigree members. A founder is an individual in a family tree who does not have any 
living ancestors and is not related to anyone in his or her generation (Figure 18).    
 
 Figure 18: Founders in a pedigree.  
 
 I considered founders initially, because they were unrelated. Such an approach 
minimizes the correlations among family members in the SNP association analysis. 
Several data sets were used in this study.  
1) 8250 pedigree founders from all 50 replicates studying all candidate genes 
1 to 7.  
FOUNDERS
NONFOUNDERS
DEAD
DEAD
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2) 8250 pedigree founders from all 50 replicates, analyzing only for genes 1 
and 2 separately. 
3) 165 pedigree founders from the best replicate 42, using only genes 1 and 2 
separately.  
4) 1000 living individuals from the best replicate 42 using only genes 1 and 2 
separately. 
 
Genotypic and phenotypic data  
 I considered the genotypic data for biallelic SNPs from 7 candidate genes for 
each individual along with his or her affectation status. The genotypic data were for 
715 candidate SNPs selected after the data reduction. The data for each SNP genotype 
were provided by the GAW12 in binary format, i.e. 11, 12, or 22 instead of the 
nucleotides. Therefore, the transition or transversion nature of the polymorphisms 
was not taken into account.    
 
Data reduction  
 The genotypic data set was very large. Considering all the 50 replicates, there 
were 50000 individuals. To minimize the dimensionality of the data set, only those 
SNPs were considered that were present in the pedigree founders in each of the 50 
replicates by using a program called DATACONVERT (SaoPedro, unpublished). As 
a result, 715 SNPs were obtained from the total of 9515 SNPs after the data 
reduction. I considered the SNPs from the both coding and non-coding regions in the 
analysis. 
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Sorting technique   
The first step in the analysis was to sort the data. I considered affection status 
as the variable of interest. I used program Scansort (Ward 2000, unpublished), which 
sorts the data according to the sum of the absolute differences between frequencies of 
healthy and affected subjects with the three SNP genotypes (11, 12, or 22, where 1 is 
a wild type, or ancestral, allele and 2 is a mutated allele).  The output of the program 
is an eleven-dimensional data set, which contains one record for each SNP position in 
the following order:  
a. SNP index (original order) 
b. Frequency of healthy individuals with genotype 11 (f11h) 
c. Frequency of healthy individuals with genotype 12 (f12h) 
d. Frequency of healthy individuals with genotype 22 (f22h) 
e. Frequency of affected (sick) individuals with genotype 11 (f11s) 
f. Frequency of affected (sick) individuals with genotype 12 (f12s) 
g. Frequency of affected (sick) individuals with genotype 22 (f22s) 
h. Sum of all the absolute differences (d) 
i. Absolute difference between c and f 
j. Absolute difference between d and g  
k. Absolute difference between e and h 
Table 6 represents this information in tabular form. 
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 Table 6: Calculation of maximum difference by Scansort program.  
Individual Genotype 
 11 12 22 
Healthy f11h f12h f22h 
Sick (Affected) f11s f12s f22s 
 
 Scansort calculates d, the sum of the absolute differences, by using the 
following formula. 
 
d = (| f11h – f11s| + |f12h-f12s| + |f22h-f22s|) / Number of individuals in the data set 
  
Scansort sorts the SNP data according to the d value. Therefore, Scansort 
orders the SNP data in a useful way where SNPs that have very different proportions 
in healthy and affected individuals are present at the top of the list. As a result, the 
output of the Scansort was used for the conventional 3´2 chi-square analysis. 
 
Comparative statistical analysis of genotype frequencies  
I used the chi-square statistic to find out the significant SNPs associated with 
the disease. The Bonferroni correction was applied to correct the significance levels 
for multiple testing. Statistical analysis was performed using Microsoft Excel.  
Chi-square statistic is calculated by using the following formula, 
     (observed frequency – expected frequency)  2 
expected frequency 
    c2 = 
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 The chi-square analysis for individual SNP position was performed by 
considering a 3´2 contingency table (Table 7). 
 
 Table 7: Chi-square analysis for an individual SNP position. 
Genotype 
Individual 
11 12 22 
 
Healthy f11h f12h f22h R1 = f11h + f12h + f22h 
Sick (Affected) f11s f12s f22s R2 = f11s + f12s + f22s 
 C1 = f11h + f11s C2 = f12h + f12s C3 = f22h + f22s A = C1+C2+C3 = R1+R2 
 
Let A = C1+C2+C3 = R1+R2 (total individuals in a population), then 
Expected frequency for f11h, f11he = C1´R1/A 
               
 
 
 The chi-square distribution is calculated by using appropriate degrees of 
freedom. The degree of freedom is calculated by using following formula (Zar 1999), 
Degrees of freedom = (columns – 1) ´ (rows – 1) 
 The Bonferroni correction was used to adjust the significance level, as there 
are a large number of tests to be performed because of the high number of loci (Weir 
1996). a was calculated by using following formula. 
a = 1- (1 - a’)1/L 
where a’ = 0.05, and L is the number of SNPs analyzed. 
(Observed frequency–expected frequency)2 
(expected frequency) 
= å        c2 
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RESULTS 
To find the significant SNPs associated with the disease I performed chi-
square analysis initially on a data set containing the founders from all the 50 
replicates. Each of the 715 SNPs in genes 1 through 7 were analyzed for the 
differences in their genotype frequencies between healthy and affected subjects for 
the data set with all the pedigree founders from the 50 replicates. These SNPs were 
then sorted by the Scansort program for the sum of their absolute differences between 
their genotype frequencies. The top twenty SNPs from this analysis are shown in 
table 8.  
Table 8: Scansort output for data set 1 (8250 pedigree founders) for top 20 SNPs 
sorted by the value of d. All the 20 SNPs are from gene 1. 
 
SNP ID 11h 12h 22h 11s 12s 22s d (diff)
557 93 1657 4103 368 1281 748 0.777903
76 4113 1647 93 754 1278 365 0.776313
2619 4219 1547 87 864 1235 298 0.720753
1553 4236 1536 81 871 1229 297 0.720721
3573 4197 1565 91 863 1236 298 0.71407
3835 4189 1572 92 860 1238 299 0.713839
3853 92 1575 4186 302 1236 859 0.713648
3742 92 1576 4185 302 1236 859 0.713307
3456 4238 1530 85 889 1224 284 0.706386
5757 4122 1620 111 842 1240 315 0.705964
7281 4081 1654 118 838 1237 322 0.695291
2942 139 1738 3976 330 1264 803 0.688615
2923 137 1766 3950 336 1258 803 0.679731
11180 4007 1710 136 837 1229 331 0.670839
1478 172 1845 3836 356 1257 784 0.65663
189 268 2154 3431 468 1303 626 0.650071
596 3433 2151 269 627 1309 461 0.64992
4471 200 1913 3740 360 1272 765 0.639679
4752 203 1922 3728 361 1273 763 0.637248
3534 262 2079 3512 396 1274 727 0.593477
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After having obtained the ordered SNP data for 715 SNPs from all the genes 
by Scansort, I performed chi-square analysis on the frequency data obtained from the 
Scansort output. The results for the most significant SNPs according to the p-values 
in genes 1, 2, and 6 are shown in tables 8, 9, and 10, respectively. I did not found any 
significant SNP in any other genes except 1,2, and 6. The resulting Bonferroni 
correction for each SNP was 7.17363´10-5 when the initial significance level was set 
to 0.05.  
Table 9: The 20 most significant SNPs in gene 1. The data set analyzed was the 
8250 pedigree founders from all the 50 replicates. 
 
 
SNP ID 11h 12h 22h 11s 12s 22s Chi Square p-value
557 93 1657 4103 368 1281 748 1315.64227 2.0507*10-286
76 4113 1647 93 754 1278 365 1308.13783 8.7394*10-285
1553 4236 1536 81 871 1229 297 1124.2512 7.4465*10-245
2619 4219 1547 87 864 1235 298 1112.56292 2.5706*10-242
3853 92 1575 4186 302 1236 859 1090.46042 1.62*10-237
3742 92 1576 4185 302 1236 859 1089.66349 2.4131*10-237
3573 4197 1565 91 863 1236 298 1088.87717 3.5754*10-237
3835 4189 1572 92 860 1238 299 1087.27638 7.9603*10-237
3456 4238 1530 85 889 1224 284 1068.70713 8.5742*10-233
5757 4122 1620 111 842 1240 315 1052.39334 2.9901*10-229
7281 4081 1654 118 838 1237 322 1024.87688 2.8236*10-223
2942 139 1738 3976 330 1264 803 984.310527 1.8183*10-214
2923 137 1766 3950 336 1258 803 976.29031 1.0028*10-212
11180 4007 1710 136 837 1229 331 954.378676 5.7451*10-208
189 268 2154 3431 468 1303 626 916.243316 1.0972*10-199
596 3433 2151 269 627 1309 461 905.951689 1.884*10-197
1478 172 1845 3836 356 1257 784 902.347863 1.1419*10-196
4471 200 1913 3740 360 1272 765 838.786422 7.2417*10-183
4752 203 1922 3728 361 1273 763 831.839741 2.335*10-181
12185 3543 2059 251 747 1237 413 750.82136 9.1456*10-164
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Table 10: The 15 most significant SNPs in gene 2. The data set analyzed was the 
8250 pedigree founders from all the 50 replicates.  
 
 
Table 11: The 12 most significant SNPs in gene 6. The data set analyzed was the 
8250 pedigree founders from all the 50 replicates. 
 
SNP ID 11h 12h 22h 11s 12s 22s Chi Square p-value
4894 680 2643 2530 170 873 1354 127.7856 1.7853*10-28
4977 3605 2003 245 1782 565 50 125.28594 6.2302*10-28
4766 672 2634 2547 172 873 1352 120.04499 8.5617*10-27
3185 614 2594 2645 158 848 1391 117.5252 3.0180*10-26
861 569 2556 2728 145 828 1424 116.38561 5.3356*10-26
1495 567 2555 2731 144 829 1424 115.68125 7.5881*10-26
715 2730 2554 569 1423 830 144 115.47719 8.4032*10-26
4030 627 2597 2629 158 865 1374 112.08614 4.5793*10-25
4538 633 2604 2616 167 859 1371 111.29881 6.7884*10-25
5961 3826 1834 193 1844 518 35 110.24763 1.1482*10-24
2540 570 2539 2744 152 856 1389 88.29132 6.7264*10-20
3155 2914 2454 485 1454 814 129 84.504551 4.4675*10-19
5219 957 2869 2027 281 1059 1057 73.380148 1.1633*10-16
2805 738 2684 2431 216 948 1233 71.968459 2.356*10-16
5499 978 2877 1998 287 1073 1037 70.221367 5.6444*10-16
SNP ID 11h 12h 22h 11s 12s 22s Chi Square p-value
6805 4948 873 32 1725 625 47 185.364929 5.6042*10-41
7332 4948 873 32 1725 625 47 185.364929 5.6042*10-41
8067 4951 870 32 1727 623 47 184.886869 7.1174*10-41
5782 4947 874 32 1725 625 47 184.845233 7.26721E-41
7073 4946 874 33 1724 626 47 184.492956 8.6668*10-41
5007 4942 879 32 1724 626 47 183.275133 1.5933*10-40
8226 35 893 4925 47 633 1717 179.169005 1.2414*10-39
1987 202 1793 3858 146 879 1372 67.4235199 2.2864*10-15
1748 3855 1797 201 1372 879 146 67.1851486 2.5759*10-15
993 3854 1796 203 1373 877 147 66.4377271 3.7430*10-15
11782 513 2420 2920 155 909 1333 26.8361224 1.4880*10-06
13869 514 2415 2924 158 911 1328 24.2681663 5.3732*10-06
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The range of significant SNPs for each gene is reported in table 12. According 
to the significance level of 7.17363´10-5 (Bonferroni cut-off correction), only 172 
SNPs out of 715 SNPs were significant, and thus could be associated with the disease. 
Table 12. Number of significant sequence polymorphisms, the range of their 
significance values, and the total number of polymorphisms, by gene, 
determined from the 8250 pedigree founders from all the 50 replicates.  
Gene  # of significant SNPs  Range of significant p-values Total # of SNPs  
1 107 2.0507x10-286 to 6.21184x10-5 157 
2 52 1.78529x10-28 to 4.29522x10-5 90 
6 13 5.60425x10-41 to 5.37322x10-6   34 
 
I considered only founders initially as they were responsible to transmit the 
SNPs if any in the next generation. Hence I analyzed the SNP data considering all the 
founders from the 50 replicates in the hope to find all the SNPs significant with 
respect to the disease causing polymorphisms. Analysis of all the pedigree founders 
showed that most of the SNPs in genes 1 and 2 might be associated with the disease. 
Therefore, to narrow down the SNPs of most interest, I analyzed 8250 pedigree 
founders for SNPs only in genes 1 and 2 separately following the same procedure as 
in 1. The results of this analysis are shown in table 13. 
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Table 13: Number of significant SNPs in genes 1 and 2 analyzed separately for 
8250 pedigree founders. (cut-off p-values from Bonferroni correction are 
0.000327 for gene 1 and 0.000570 for gene 2)  
Gene  # of significant SNPs  Range of p-values Total # of SNPs  
1 114 2.0507x10-286 to 0.000287 157 
2 61 1.78529x10-28 to 0.000398 90 
 
I also analyzed the SNP data for genes 1 and 2 separately for the founders in 
best replicate 42 in an attempt to identify the most significant SNPs associated with 
the disease in the best replicate and then to compare it with the significant SNPs 
obtained after analyzing 8250 pedigree founders. These results are shown in table 14. 
 
Table 14: Number of significant SNPs in genes 1 and 2 analyzed separately for 
165 pedigree founders in best replicate 42. (cut-off p-values from Bonferroni 
correction are 0.000327 for gene 1 and 0.000570 for gene 2) 
 
  
 
 
 
 
I also analyzed the SNP data from all individuals in replicate 42 for genes 1 
and 2 separately and then compare it with the results obtained for the same analysis 
performed with 8250 pedigree founders and 165 founders from replicate 42 
Gene  # of significant SNPs  Range of p-values Total # of SNPs  
1 35 9.54x10-8 to 0.000325 157 
2 0 -- 90 
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separately to see the effect of sample size on the number of significant SNPs. The 
results are shown in table 15. 
  
Table 15: Number of significant SNPs in genes 1 and 2 analyzed separately for 
1000 individuals in best replicate 42. (cut-off p-values from Bonferroni 
correction are 0.000327 for gene 1 and 0.000570 for gene 2) 
 
Gene  # of significant SNPs  Range of p-values Total # of SNPs  
1 55 2.18x10-35 to 0.000125 157 
2 1 6.01x10-6 90 
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DISCUSSION 
 The analysis was performed to find the most significant SNPs associated with 
the disease in the simulated GAW12 data set. I used a genotype disequilibrium 
approach in which I considered the difference in genotype frequencies of the SNPs. 
According to the results obtained, I found possible mutations in genes 1, 2, and 6 that 
were associated with the disease. This analysis was performed without the GAW 12 
answers, which were made available to us after the analysis was completed.  
 The chi-square analysis on data set of 8250 pedigree founders identified 107 
significant SNPs in gene 1 (out of a total of 157 SNPs in that gene), 52 SNPs in gene 
2 (out of a total of 90 SNPs in gene 2) and 13 SNPs in gene 6 (out of a total of 36 
SNPs in gene 6). Because genes 1, 2, and 6 contain multiple polymorphisms which 
are associated with the disease, it is difficult to identify causative mutations for the 
disease. Hence, one hypothesis that I pursued was that the sequence polymorphisms 
showing the lowest p-values were the most likely candidates for affecting the disease 
state. In this regard, I identified SNPs at nucleotide position 557 in gene 1 (lowest p-
value of 2.05x10-286), nucleotide positions 6805 and 7332 in gene 6 (p-value = 
5.60x10-41) and nucleotide position 4894 in gene 2 (p = 1.79 x10-28) that were most 
likely associated with the disease. Many of the SNPs located near these mutations 
also have very low p-values, most likely because of the linkage disequilibrium 
between SNP variants. For example, in gene 1 the SNP at position 557 has the lowest 
p-value of 2.05 x10-286. This is the sixth polymorphism occurring in this gene, 
counting from the start of the gene. The second polymorphism from the start of this 
gene, at position 76, has the next lowest p-value of 8.74 x10-285. The third 
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polymorphism from the start of the gene, at nucleotide position 189, has a p-value of 
1.10 x10-199, and the seventh polymorphism, at position 596, has p-value = 1.88 x10-
197. The fourth, eighth, ninth and tenth polymorphisms at nuc leotide positions 286, 
610, 730 and 885 respectively, also show significant association with the disease 
(with p-value<0.000327). This observation suggests a likely functional role of the 5' 
end of gene 1 in the disease.  
 There was generally a good correlation between the SNPs identified by the 
chi-square test and the polymorphisms that had the top scores identified by program 
Scansort. The majority of SNPs that showed significant association with the disease 
by the chi-square test were located in the top portion of the arrays generated by 
Scansort. The most significant SNPs from genes 1, 2, and 6 (sequence positions 557 
in gene 1, 4894 in gene 2 and 6805 and 7332 in gene 6, respectively) were ranked as 
number 1, 61, 47 and 48 when sorted by their chi-square values in data set of 8250 
pedigree founders. After sorting by Scansort in the same data set for the sum of the 
absolute differences in genotype frequencies in healthy and affected individuals, their 
positions were 1, 48, 56 and 57, respectively, in the sorted data set. When the 172 top 
SNP positions that were significant in data set containing all pedigree founders from 
all the 50 replicates according to the chi-square method were compared to the top 172 
SNP positions identified by the Scansort, all but 24 SNPs were found to be shared 
between the two lists, with the proportion of shared SNPs equal to 87%.  
 The sensitivity of our tests seemed to increase with the increase of the number 
of individuals in the data set. This was the case whether relatives or non-relatives 
were added to the data set. I found 25 SNPs in gene 1 which were significant in data 
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set 1 with founders from all 50 replicates, but not significant in either data set 3 or 4. 
Analysis of the data set containing all the 715 SNPs with all the founders from 50 
replicates revealed 107 significant SNPs in gene 1, while that number was 114 in data 
set containing the SNPs for gene 1 only with all the founders from 50 replicates, 35 in 
data set containing just founders from replicate 42, and 55 in data set containing all 
the individuals in replicate 42. In case of gene 2, I identified 52 significant SNPs in 
data set containing the 715 SNPs with all the founders from the 50 replicates, 61 
significant SNPs in data set containing all the founders from 50 replicates for gene 2 
only, 0 in data set containing just founders from replicate 42 and 1 in data set which 
contained all the individuals in replicate 42. The p-values were also smaller in the 
larger data sets. Therefore, it seems beneficial to add individuals to the data set even 
if they are related to one another. 
 The answers to this problem provided by the GAW12 organizers (GAW12 
Abstracts) were very close to the answers obtained in this analysis. The SNPs 
associated with the disease were in genes 1, 2, and 6 according to the GAW12 
answers (Figure 17) where candidate gene 1 corresponds to the major gene 6, 
candidate gene 2 corresponds to the major gene 5 and candidate gene 6 corresponds 
to major gene 1. My analysis also showed association of these three genes with the 
disease. The exact positions of the SNPs in these genes according to the answers were 
at nucleotide position 557 in gene 1, and position 5782 in gene 6. In gene 2, there 
were number of multi-allelic functional variants; in the regulatory elements or in the 
first or second bp of a codon; leading to amino acid substitutions in gene 2 and were 
associated with the disease. The effect of these genes is shown in figure 17.  The 
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analysis presented here also showed the SNP at 557 position in gene 1 as the most 
likely candidate; however, the SNPs in gene 6 identified at positions 6805 and 7332 
were not correct when compared to the GAW12 answers. Despite discrepancies 
related to individual SNPs, the analysis presented here correctly identified the 
importance of all the three genes1, 2, and 6 in disease, and these results show 
importance of genotypic linkage disequilibrium methods in fine gene mapping. 
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APPENDICES 
Appendix 1: An example of the SNP data for human chromosome 6 from the Whitehead 
Institute of Genome Research. In all there were 146 SNPs. (cR corresponds to the 
radiation hybrid distance). VNTR (variable number of tandem repeats) are the top and 
bottom markers for that particular SNP position. 
 
SNP NAME TYPE GENETIC 
DISTANCE (cM) 
TOP VNTR BOTTOM 
VNTR 
WIAF 1583 A/G 1.4 D6S344 D6S344 
WIAF 857 C/T 1.37(cR) D6S344 D6S344 
WIAF 1034 C/T 0.00(cR)  D6S344 D6S344 
WIAF 2096 G/A 6.4 D6S1617 D6S1617 
WIAF 131 T/C 41.75(cR) D6S1617 D6S1617 
WIAF 132 T/C 41.75(cR) D6S1617 D6S1617 
WIAF 950 A/C 51.37(cR) D6S296 D6S470 
WIAF 549 C/T 9.0 D6S296 D6S470 
WIAF 890 G/C 59.80(cR) D6S1674 D6S1674 
WIAF 1939 C/G 54.83(cR) D6S1674 D6S1674 
WIAF 1020 A/G 17.7 D6S470 D6S470 
WIAF 881 G/A 67.56(cR) D6S470 D6S1578 
WIAF 1567 G/A 20.5 D6S470 D6S1578 
WIAF 967 T/C 66.11(cR) D6S470 D6S1578 
WIAF 1891 C/T 81.31(cR) D6S469 D6S288 
WIAF 116 G/A 85.33(cR) D6S469 D6S288 
WIAF 1541 C/G 34.2 D6S1688 D6S1688 
WIAF 1966 G/A 111.66(cR) D6S1688 D6S422 
WIAF 709 T/A 34.0 D6S1688 D6S422 
WIAF 105 C/T 118.48(cR) D6S422 D6S1686 
WIAF 106 C/A 118.48(cR) D6S422 D6S1686 
WIAF 415 T/C 121.60(cR) D6S1686 D6S1686 
WIAF 1896 A/T 123.20(cR) D6S1686 D6S1691 
WIAF 613 G/T 40.0 D6S1686 D6S1691 
WIAF 614 A/G 40.0 D6S1686 D6S1691 
WIAF 1959 T/C 128.64(cR) D6S1691 D6S464 
WIAF 1574 T/C 130.56(cR) D6S464 D6S464 
WIAF 1460 A/G 46 D6S276 D6S439 
WIAF 1461 T/A 46 D6S276 D6S439 
WIAF 1462 G/T 46 D6S276 D6S439 
WIAF 2020 C/G 161.68(cR) D6S276 D6S439 
WIAF 2021 T/C 161.68(cR) D6S276 D6S439 
WIAF 139 A/C 165.13(cR) D6S276 D6S439  
WIAF 1551 T/C 46.6 D6S276 D6S439 
WIAF 1552 G/A 46.6 D6S276 D6S439 
WIAF 1553 G/A 46.6 D6S276 D6S439 
WIAF 1554 T/C 46.6 D6S276 D6S439 
WIAF 1722 A/T 46.7 D6S276 D6S439 
 
 
 65
 
 
WIAF 110 C/T 179.84(cR) D6S276 D6S439 
WIAF 556 C/T 177.90(cR) D6S276 D6S439 
WIAF 557 C/T 177.90(cR) D6S276 D6S439 
WIAF 558 T/C 177.90(cR) D6S276 D6S439 
WIAF 257 C/A 178.21(cR) D6S276 D6S439 
WIAF 258 A/C 178.21(cR) D6S276 D6S439 
WIAF 1185 C/G 46.9 D6S276 D6S439 
WIAF 1453 A/G 46.9 D6S276 D6S439 
WIAF 1935 C/T 47.0 D6S276 D6S439 
WIAF 897 C/T 178.21(cR) D6S276 D6S439 
WIAF 898 A/G 178.21(cR) D6S276 D6S439 
WIAF 1696 C/G 47.0 D6S276 D6S439 
WIAF 643 A/G Unassigned D6S276 D6S439 
WIAF 1306 A/G 47.1 D6S276 D6S439 
WIAF 1084 C/T 47.2 D6S276 D6S439 
WIAF 1009 T/C 47.2 D6S276 D6S439 
WIAF 1335 G/C 179.74(cR) D6S276 D6S439 
WIAF 1336 A/G 179.74(cR) D6S276 D6S439 
WIAF 1337 C/A 179.74(cR) D6S276 D6S439 
WIAF 1338 A/G 179.74(cR) D6S276 D6S439 
WIAF 1339 G/A 179.74(cR) D6S276 D6S439 
WIAF 1340 T/C 179.74(cR) D6S276 D6S439 
WIAF 1341 G/A 179.74(cR) D6S276 D6S439 
WIAF 1342 T/C 179.74(cR) D6S276 D6S439 
WIAF 2177 G/C 47.7 D6S276 D6S439 
WIAF 2106 C/T 47.7 D6S276 D6S439 
WIAF 2103 A/G 47.8 D6S276 D6S439 
WIAF 1006 T/C 188.58(cR) D6S276 D6S439 
WIAF 1746 A/G 194.89(cR) D6S276 D6S439 
WIAF 916 T/C 193.76(cR) D6S276 D6S439 
WIAF 1586 G/A 52.8 D6S291 D6S1610 
WIAF 1587 T/C 52.8 D6S291 D6S1610 
WIAF 2075 G/A 65.5 D6S426 D6271 
WIAF 1780 A/C 252.98(cR) D6S426 D6271 
WIAF 1608 A/G 246.37(cR) D6271 D6271 
WIAF 1609 A/G 246.37(cR) D6271 D6271 
WIAF 1060 G/A 258.00(cR) D6271 D6271 
WIAF 98 T/C 251.95(cR) D6271 D6S459 
WIAF 1359 T/C 69.0 D6271 D6S459 
WIAF 1360 T/C 69.0 D6271 D6S459 
WIAF 538 C/T 69.0 TO 72.0 D6S459 D6S438 
WIAF 539 C/A 69.0 TO 72.0 D6S459 D6S438 
WIAF 997 G/T 271.85(cR) D6S459 D6S438 
WIAF 520 C/T 77.0 D6S436 D6S466 
WIAF 805 C/T 307.81 D6S466 D6S466 
WIAF 2212 T/C 79.9 D6S257 D6S257 
WIAF 589 T/A 462.24(cR) D6S1589 D6S1589 
 66
WIAF 922 A/C 533.70(cR) D6S1589 D6S1589 
WIAF 1486 A/G 557.69(cR) D6S1601 D6S1570 
WIAF 1669 G/A 557.21(cR) D6S1601 D6S1570 
WIAF 1670 G/A 557.21(cR) D6S1601 D6S1570 
WIAF 220 G/T 539.89(cR) D6S1601 D6S1570 
WIAF 1654  A/C 102.4 D6S417 D6S424 
WIAF 78 C/T 626.11(cR) D6S417 D6S424 
WIAF 1427 G/C 618.65(cR) D6S417 D6S424 
WIAF 1476 T/C 629.40(cR) D6S1716 D6S468 
WIAF 207 G/A 116.2 D6S278 D6S278 
WIAF 844 A/C 682.24 D6S278 D6S278 
WIAF 845 A/C 682.24 D6S278 D6S278 
WIAF 1875  C/T 116.6 D6S278 D6S302 
WIAF 1876 G/A 116.6 D6S278 D6S302 
WIAF 1877 G/C 116.6 D6S278 D6S302 
WIAF 1878 T/C 116.6 D6S278 D6S302 
WIAF 1879 C/T 116.6 D6S278 D6S302 
WIAF 1880 A/G 116.6 D6S278 D6S302 
WIAF 1881 C/T 116.6 D6S278 D6S302 
WIAF 2219 T/G 116.6 D6S278 D6S302 
WIAF 2126 G/A 116.9 D6S278 D6S302 
WIAF 584  T/C 707.96(cR) D6S423 D6S423 
WIAF 726 C/T 121 D6S423 D6S423 
WIAF 985 T/A 705.43(cR) D6S423 D6S1712 
WIAF 1203 G/T 121.0 D6S423 D6S1712 
WIAF 2171 G/A 124.2 D6S423 D6S1712 
WIAF 224 C/T 122.0(cR) D6S423 D6S1712 
WIAF 225 T/C 122.0(cR) D6S423 D6S1712 
WIAF 736 C/G 731.63(cR) D6S423 D6S1712 
WIAF 737 G/A 731.63(cR) D6S423 D6S1712 
WIAF 492 A/T 733.67(cR) D6S407 D6S262 
WIAF 1674 T/C 736.71(cR) D6S407 D6S262 
WIAF 738 A/G 129.0 D6S407 D6S262 
WIAF 1366 G/A 744.83(cR) D6S407 D6S262 
WIAF 642 T/C 138.0 D6S292 D6S1699 
WIAF 1604 G/C 144.5 D6S453 D6S453 
WIAF 466 A/G 748.63(cR) D6S453 D6S308 
WIAF 1873 G/A 788.32(cR) D6S453 D6S308 
WIAF 3 T/G 790.34(cR) D6S453 D6S308 
WIAF 2034 T/C 145.6 D6S308 D6S308 
WIAF 1704 T/G 150.4 D6S311 D6S1687 
WIAF 1623 A/G 150.4 D6S311 D6S1687 
WIAF 592 A/G 811.66(cR) D6S311 D6S1687 
WIAF 982 C/T 814.38(cR) D6S1687 D6S1687 
WIAF 563 A/C 155.0 D6S1687 D6S448 
WIAF 762 C/G 837.32(cR) D6S419 D6S1579 
WIAF 1954 T/C 165.7 D6S419 D6S1579 
WIAF 1955 G/A 165.7 D6S419 D6S1579 
WIAF 1493 T/A 165.7 D6S419 D6S1579 
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WIAF 1494 A/G 165.7 D6S419 D6S1579 
WIAF 888 T/C 165.7 D6S419 D6S1579 
WIAF 915 G/A 175.9 D6S1579 D6S1719 
WIAF 97 G/A 833.43(cR) D6S1579 D6S1719 
WIAF 397 C/T 843.63 D6S1719 D6S1719 
WIAF 1690 A/C 178.4 D6S1719 D6S264 
WIAF 30 C/T 846.82(cR) D6S1719 D6S264 
WIAF 12 T/C 167.0 D6S1719 D6S264 
WIAF 13 A/G 167.0 D6S1719 D6S264 
WIAF 1739 A/G 184.8 D6S1585 D6S446 
WIAF 1740 A/G 184.8 D6S1585 D6S446 
WIAF 2186 A/G 189.0 D6S446 D6S1693 
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Appendix 2: The SNP data of human chromosome 6 from the Genome Database (PV = 
point variation) 
 
 GENE 
NAME 
SNP TYPE/ LOCATION CHANGE IN AMINO 
ACID 
SNP 
ABCB2 
(TAP1) 
PV Codon 333 ILE. to VAL.(ATC to 
GTC) 
A/G 
 PV  Codon 370 ALA to VAL (GCT to 
GTT) 
C/T  
 PV Codon 458 VAL to LEU (GTG to 
TTG) 
G/T 
 PV Codon 637 ASP to 
GLY(GAC 
to GGC) 
A/G 
 PV 
 
Codon 648 ARG to 
GLN (CGA to CAA) 
G/A 
     
ABCB3 
(TAP2) 
PV Codon 163 VAL to VAL (GTC to 
GTT) 
C/T 
 PV Codon 379 ILE to VAL (ATA to 
GTA) 
A/G 
 PV Codon 386 GLY to GLY (GGG to 
GGT) 
G/T 
 PV Codon 387 VAL to VAL (GTG to 
GTA) 
G/A 
 PV Codon 436 ASN to ASN (AAC to 
AAT) 
C/T 
 PV Codon 565 ALA to THR (GCT to 
ACT) 
G/A 
 PV Codon 651 ARG to CYS (CGT to 
TGT) 
C/T 
 PV Codon 665 ALA to THR (GCA to 
ACA) 
G/A 
 PV Codon 687 GLN to STOP (CAG to 
TAG) 
C/T 
 PV  Codon 697 VAL to VAL (GTT to 
GTG) 
T/G 
     
C4A 4B  Codon 1101 C to T C/T 
  Codon 1186 G to C G/C 
 RFLP Exon 
40-> 
nt 5095 
CTG to CTA (no aa 
change) 
G/A 
     
CDKN1A PV Codon31 SER to ARG (C to A) C/A 
 PV Codon 91 A to T A/T 
     
COL10A1 PV  GLY to ARG  
 PV2 exon 2 position 608 GTG to GTC G/C 
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CYP21A1P/ 
A2 
PV exon 7 
codon 269 
SER to THR (G to C) G/C 
     
ESR1 PV End of  
 Intron 1 and before 
exon2 (nt 257) 
ALA to VAL (C to T) C/T 
 PV Nt 261 G to C (Silent) G/C 
     
GMPR PV Nt 766 from chain 
initiat. Codon 
PHE to ILE (T to A) T/A 
 PV  C to T (silent) C/T 
     
HSPA1B RFLP Nt 1267 A To G A/G 
     
LPA PV Codon 4168 THR to MET (C to T) C/T 
     
LTA/ TNFB 
(ii) 
RFLP Intron 1 position 26 ASN to THR (AAC to 
ACC) 
A/C 
     
MEP1A PV Codon 176 A To G A/G 
  D6S282 To D6S272 A to G A/G 
     
MLN PV Nt115 of gene 
Position-11of signal 
peptide 
VAL to ALA (T to C) 
 
T/C 
 PV Nt 184 of 1st Exon C To G C/G 
     
RDS PV Position 558 of gene C To T (no aa change) C/T 
     
TNF 
(TNFA) 
PV Nt –308 of 5' of the 
gene 
G To A G/A 
 PV Nt –238 G To A G/A 
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Appendix 3: An example of the SNP data of human chromosome 6 from fifth release of 
the SNP Consortium. 
 
SNP dbSNP # Chrom Band GenBank 
Version 
Links  Type of 
Change 
TSC0089213 119642 Chr6 6p35.2 AL080251.3   a/g 
TSC0089214 119643 Chr6 6p35.2 AL080251.3   c/t 
TSC0016149 74583 Chr6 6q22.22 AL135839.2   a/g 
TSC0148520 110255 Chr6 6q22.22 AL135839.2   a/g 
TSC0089004 119501 Chr6 6q22.22 AL135839.2   a/g 
TSC0010080 54655 Chr6 6q22.22 AL135839.2   a/g 
TSC0026679 80938 Chr6 6q22.22 AL135839.2   a/g 
TSC0097341 125463 Chr6 6p35.2 AL080251.3   g/t 
TSC0119139 93589 Chr6 6q22.22 AL135839.2   c/g 
TSC0102942 129620 Chr6   AC004842.2 NT_002179 g/t 
TSC0110225 133601 Chr6 6p25 AL021328.1 NT_000213 a/c 
TSC0110226 133602 Chr6 6p25 AL021328.1 NT_000213 a/c 
TSC0090977 120849 Chr6 6p25 AL035696.14 NT_002179 a/g 
TSC0067822   Chr6 6p25 AL035696.14 NT_002179 c/t 
TSC0110227 133603 Chr6 6p25 AL021328.1 NT_000213 a/g 
TSC0043505 59435 Chr6 6p25 AL035696.14 NT_002179 a/g 
TSC0001995 25023 Chr6 6p25 AL035696.14 NT_002179 g/t 
TSC0067821   Chr6 6p25 AL035696.14 NT_002179 a/g 
TSC0102721 129487 Chr6   AC004842.2 NT_002179 a/g 
TSC0069979   Chr6 6p25 AL021328.1 NT_000213 c/t 
 
Note: This example represents 20 SNPs out of 5102 SNPs collected from the SNP 
Consortium database for this project. 
